Evaxion will present three-year follow-up data from its Phase 2 trial of EVX-01, a personalized cancer vaccine candidate, in advanced melanoma at ESMO 2026. That is the headline fact, and for a small Danish biotech it is a significant one: a slot at the European Society for Medical Oncology congress means the company's most advanced oncology asset has survived long enough to report durable outcomes.

EVX-01 is Evaxion's individualized neoantigen cancer immunotherapy. The approach uses the company's AI-driven discovery platform to select tumor-specific targets for each patient, then builds a vaccine designed to train the immune system against that patient's cancer. Advanced melanoma, the trial's indication, remains one of the most closely watched proving grounds for neoantigen vaccines, alongside modern checkpoint inhibitor therapy.

The company has not yet disclosed the specific efficacy figures in the release announcing the presentation. In plain terms: the announcement confirms the timing and venue of the data drop, not the results themselves. Those numbers arrive with the poster or oral session at the congress.

What does a three-year readout mean here?

Long-term durability is the currency of cancer vaccine development. Early Phase 2 timepoints can look promising on response metrics that fade by month 24 or 36, so a three-year dataset in advanced melanoma carries more weight than an interim look. Melanoma, of course, is the skin cancer dermatologists track most closely for metastatic risk, and it sits at the intersection of dermatology and medical oncology that Derm Field readers know well.

For context on scale: ESMO's annual congress is one of the two largest oncology meetings globally, and late-breaking and multi-year follow-up data there routinely move both clinical practice conversations and small-cap share prices. A presentation slot is a visibility event for Evaxion as much as a scientific one.

Takeaway: durability data at three years is exactly the kind of evidence neoantigen vaccines have needed, but the verdict waits for the actual numbers in the session.

Why dermatology readers should care

Melanoma management has shifted dramatically toward earlier interception, with AJCC staging, Breslow thickness and sentinel-node status driving who gets adjuvant therapy. Vaccine candidates like EVX-01 represent a possible future layer on top of checkpoint blockade, and their trial populations are drawn from the same advanced-stage patients dermatologists help identify and refer.

The announcement itself carries no new PASI- or EASI-style endpoint, no survival figure, no regulatory action. It is a calendar item with real weight. What it signals is that Evaxion considers the three-year package strong enough for a major international audience, and that peer-reviewed scrutiny is the next step.

Whether EVX-01's long-term data strengthens the case for personalized cancer vaccines in advanced melanoma will become clear when the results are presented at ESMO 2026.